Morgan Stanley Tg Therapeutics, Inc. Transaction History

Morgan Stanley

$1.36 Trillion
Q1 2025

A detailed history of Morgan Stanley transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 2,050,548 shares of TGTX stock, worth $68.9 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

2,050,548

Previous 2,164,434 5.26%

Holding current value

$68.9 Million

Previous $65.1 Million 24.1%

% of portfolio

0.01%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$27.67 - $42.99 $3.15 Million - $4.9 Million	-113,886 Reduced 5.26%	2,050,548 $80.9 Million
Q4 2024 Feb 14, 2025	SELL	$21.31 - $35.09 $724 - $1,193	-34 Reduced -0.0%	2,164,434 $65.1 Million
Q3 2024 May 14, 2025	BUY	$17.21 - $25.28 $11.6 Million - $17.1 Million	675,726 Added 45.39%	2,164,468 $50.6 Million
Q3 2024 Nov 14, 2024	BUY	$17.21 - $25.28 $11.6 Million - $17.1 Million	675,726 Added 45.39%	2,164,468 $50.6 Million
Q2 2024 May 14, 2025	SELL	$13.32 - $19.19 $9 Million - $13 Million	-675,692 Reduced 31.22%	1,488,742 $26.5 Million
Q2 2024 Oct 17, 2024	BUY	$13.32 - $19.19 $4.22 Million - $6.08 Million	317,005 Added 27.05%	1,488,742 $26.5 Million
Q2 2024 Aug 14, 2024	BUY	$13.32 - $19.19 $4.22 Million - $6.08 Million	317,005 Added 27.05%	1,488,742 $26.5 Million
Q1 2024 Oct 17, 2024	SELL	$13.02 - $21.3 $4.13 Million - $6.75 Million	-317,005 Reduced 21.29%	1,171,737 $17.8 Million
Q1 2024 Aug 16, 2024	SELL	$13.02 - $21.3 $4.14 Million - $6.77 Million	-317,746 Reduced 21.33%	1,171,737 $17.8 Million
Q1 2024 May 15, 2024	SELL	$13.02 - $21.3 $4.14 Million - $6.77 Million	-317,746 Reduced 21.33%	1,171,737 $17.8 Million
Q4 2023 Aug 16, 2024	BUY	$6.68 - $18.81 $4,949 - $13,938	741 Added 0.05%	1,489,483 $25.4 Million
Q4 2023 Feb 13, 2024	SELL	$6.68 - $18.81 $2.59 Million - $7.28 Million	-387,197 Reduced 20.63%	1,489,483 $25.4 Million
Q3 2023 Nov 15, 2023	BUY	$8.36 - $26.5 $1.56 Million - $4.94 Million	186,498 Added 11.03%	1,876,680 $15.7 Million
Q2 2023 Aug 14, 2023	BUY	$15.48 - $35.0 $6.46 Million - $14.6 Million	417,406 Added 32.79%	1,690,182 $42 Million
Q1 2023 May 15, 2023	BUY	$10.23 - $19.34 $5.1 Million - $9.64 Million	498,536 Added 64.39%	1,272,776 $19.1 Million
Q4 2022 Feb 14, 2023	BUY	$5.01 - $11.83 $1.99 Million - $4.7 Million	397,442 Added 105.48%	774,240 $9.16 Million
Q3 2022 Nov 14, 2022	SELL	$4.57 - $8.4 $6.96 Million - $12.8 Million	-1,522,212 Reduced 80.16%	376,798 $2.23 Million
Q2 2022 Oct 27, 2022	BUY	$3.74 - $10.66 $3.03 Million - $8.64 Million	810,658 Added 74.48%	1,899,010 $8.07 Million
Q2 2022 Aug 15, 2022	BUY	$3.74 - $10.66 $3.03 Million - $8.64 Million	810,658 Added 74.48%	1,899,010 $8.07 Million
Q1 2022 Oct 27, 2022	SELL	$7.81 - $20.45 $6.33 Million - $16.6 Million	-810,658 Reduced 42.69%	1,088,352 $10.4 Million
Q1 2022 May 13, 2022	BUY	$7.81 - $20.45 $4.08 Million - $10.7 Million	522,110 Added 92.21%	1,088,352 $10.4 Million
Q4 2021 Feb 14, 2022	SELL	$15.2 - $35.51 $1.73 Million - $4.05 Million	-113,956 Reduced 16.75%	566,242 $10.8 Million
Q3 2021 Nov 15, 2021	BUY	$21.78 - $40.45 $14.8 Million - $27.5 Million	680,198 New	680,198 $22.6 Million

Others Institutions Holding TGTX

# of Institutions

407

Shares Held

87.5M

Call Options Held

2.33M

Put Options Held

1.75M

View Full List

About TG THERAPEUTICS, INC.

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.88B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

More about TGTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account